Checkpoint Therapeutics, Inc. Forecast, price target & analysts
Checkpoint Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Checkpoint Therapeutics, Inc. Classifications & Recommendation:
Checkpoint Therapeutics, Inc. Price Target
| Target Price | $4.33 |
| Price | $4.01 |
| Potential |
8.06%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Checkpoint Therapeutics, Inc. 2026 .
The average Checkpoint Therapeutics, Inc. target price is $4.33.
This is
8.06%
register free of charge
$4.80
19.70%
register free of charge
$4.10
2.24%
register free of charge
|
|
| A rating was issued by 3 analysts: 1 Analysts recommend Checkpoint Therapeutics, Inc. to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Checkpoint Therapeutics, Inc. stock has an average upside potential 2026 of
8.06%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.04 | 41.11 |
| 60.00% | 102,685.00% | |
| Net Margin | -192,907.00% | -23.13% |
| 28.16% | 99.99% |
2 Analysts have issued a sales forecast Checkpoint Therapeutics, Inc. 2025 . The average Checkpoint Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
2 Checkpoint Therapeutics, Inc. Analysts have issued a net profit forecast 2025. The average Checkpoint Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.42 | -0.18 |
| 48.74% | 87.32% | |
| P/E | negative | |
| EV/Sales | 8.01 |
2 Analysts have issued a Checkpoint Therapeutics, Inc. forecast for earnings per share. The average Checkpoint Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Checkpoint Therapeutics, Inc....
Current Checkpoint Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| D. Boral Capital |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Lake Street |
Locked
➜
Locked
|
Locked | Dec 16 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 11 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
D. Boral Capital:
Locked
➜
Locked
|
Jan 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 16 2024 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Dec 16 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
